<!DOCTYPE HTML>
<html lang="en">
<head>
	<meta charset="UTF-8">
	<title>VIKHI</title>
	<link rel="stylesheet" href="css/font-awesome/css/font-awesome.min.css" />

	<link rel="stylesheet" href="css/fonts/stylesheet.css" />
	<link rel="stylesheet" href="css/fonts/fonts.css" />
	<link rel="stylesheet" href="css/bootstrap/bootstrap.min.css" />
	<link rel="stylesheet" href="css/animat/animate.min.css" />
	<link rel="stylesheet" href="css/fancybox/jquery.fancybox.css" />
	<link rel="stylesheet" href="css/nivo-lightbox/nivo-lightbox.css" />
	<link rel="stylesheet" href="css/themes/default/default.css" />
	<link rel="stylesheet" href="css/owl-carousel/owl.carousel.css" />
	<link rel="stylesheet" href="css/owl-carousel/owl.theme.css" />
	<link rel="stylesheet" href="css/owl-carousel/owl.transitions.css">
	<link rel="stylesheet" href="css/style.css" />
	<link rel="stylesheet" href="css/responsive.css" />
	<link href="https://fonts.googleapis.com/css?family=Montserrat|Source+Sans+Pro" rel="stylesheet">
</head>
<body>

	<div class='preloader'><div class='loaded'>&nbsp;</div></div>

	<header id="home" class="header">
		<div class="main_menu_bg navbar-fixed-top">
			<div class="container">
				<div class="row">
					<div class="nave_menu">
					<nav class="navbar navbar-default">
					  <div class="container-fluid">
						<div class="navbar-header">
						  <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-target="#bs-example-navbar-collapse-1" aria-expanded="false">
						  </button>
						  <a class="navbar-brand" href="index.html">
							<div class="logo">
								<img src="images/vikhiLOGOsm.png" alt="" height="30"/>
							</div>
						  </a>
						</div>

					<div class="collapse navbar-collapse" id="bs-example-navbar-collapse-1">

						  <ul class="nav navbar-nav navbar-right">
							<li><a href="aspectos.html">1. General Aspects</a></li>
							<li><a href="recomendaciones.html">2. Recommendations</a></li>
							<li class="active"><a href="toxicidad00.html">3. Toxicities</a></li>
						  </ul>
						</div>
					  </div>
					</nav>
					</div>
				</div>

			</div>

		</div>
	</header>



	<section class="banner">
		<div class="container">
			<div class="row">
				<div class="main_banner_area text-center">
					<div class="col-md-12 col-sm-12">
						<div class="single_banner_text wow zoomIn" data-wow-duration="1s">
							<h2>Toxicities</h2>
							<br/>
							<div class="separator"></div>
							<h5>BASIC COURSE IN IMMUNOTHERAPY</h5>


						</div>
					</div>
				</div>
			</div>
		</div>
	</section>




	<section class="franja">
	 <div class="overlay_franja">
		 <div class="container">
			 <div class="row">
				 <div class="col-md-12 col-sm-12 col-xs-12">
					 <div class="main_franja_content text-center wow fadeIn" data-wow-duration="2s">
						 <h2>3<span class="negrita">.7</span> NEUROLOGICAL TOXICITY</h2>
						 <br/> <img src="images/nervioso.png" alt="" height="60px"/>

					 </div>
				 </div>
			 </div>
		 </div>
	 </div>
 </section>




 <section class="texto">
	 <div class="container">
		 <div class="row">
			 <div class="parrafo wow zoomIn" data-wow-duration="0.5s">
				 <h2>Introduction</h2>
				 <br/>
				 <p>Neurological toxicities are a rare type of immune-mediated toxicity. They have been reported in 2% of patients treated with ipilimumab (anti-CTLA-4), Nivolumab and Pembrolizumab (anti-PD-1).</p>
				 <br/><p>Melanoma is a very immunogenic tumour with the ability to present an immune response in the host.</p>
				 <br/><p>Some studies have shown that melanoma patients present high levels of IL-6 in the cerebrospinal fluid.</p>
				 <br/><p>High IL-6 levels produce indirect damage due to the production of nitric oxide synthase by the microglia. Some immune checkpoint inhibitors increase IL-6 expression.</p>
				 <br/><p>The clinical manifestations described as immune-mediated neurological toxicities are the following: sensory-motor neuropathies of the Guillain-Barré syndrome type, immune-mediated encephalitis, inflammatory granulomatosis of the central nervous system, Myasthenia Grave-like syndrome, reversible posterior leukoencephalopathy, aseptic meningitis, radiculoneuropathies, transverse myelitis, and Bell's palsy.</p>
				 <br/><p>Since the symptoms presented are so rare, attention by the attending physician as well as the patient is required in order to avoid serious adverse events.</p>
			 </div>
		 </div>
	 </div>
 </section>

	<section class="counterUp">
		<div class="counter_overlay">
			<div class="container">
				<div class="row">
					<div class="main_counter_content text-center">
						<div class="col-md-12 col-sm-12 col-xs-12">

							<img src="images/diagnostico.png" alt="" height="40px"/> <br/><br/>
							<h2>Diagnosis</h2>
							<br/> <br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> Blurred vision, headache, nausea, vomiting, impaired gait, vertigo, speech impairment, myoclonus, seizures, loss of consciousness..</p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> Altered memory, dizziness, confusion, hallucinations...</p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> Sensory and/or motor deficit, anaesthesia, paresis, plegia...</p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> Cranial nerve disorder</p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> Nuchal rigidity</p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> Motor spasticity…</p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> Neuropathic pain, allodynia…</p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> Asthenia, muscle weakness, fever... </p>

							<div class="contorno wow fadeIn">
							<h2>Incidence</h2>
							<br/>
							<p>Related to CTLA-4 or PD-1/PLD-1 inhibitors: below 1%.</p>
							</div>
							<br/> <br/> <br/> <br/>
							<h2>Differential diagnosis</h2>
							<br/> <br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;A&nbsp;&nbsp;</span> Infectious causes: bacterial, viral, parasitic</p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;B&nbsp;&nbsp;</span> Other pharmacological/toxic/previous radiotherapy causes</p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;C&nbsp;&nbsp;</span> Seizures, epileptic status</p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;D&nbsp;&nbsp;</span> Ischaemic or haemorrhagic strokes</p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;E&nbsp;&nbsp;</span> Myasthenia gravis</p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;F&nbsp;&nbsp;</span> Guillain-Barré Syndrome</p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;G&nbsp;&nbsp;</span> Psychiatric disorders (conversion disorder, etc.)</p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;H&nbsp;&nbsp;</span> Causes due to direct injury or compression of the nerve root / medullary cord</p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;I&nbsp;&nbsp;&nbsp;</span> Metabolic causes</p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;J&nbsp;&nbsp;</span> Idiopathic / iatrogenic causes</p>

						</div>
					</div>
				</div>
			</div>
		</div>
	</section>

	<section class="texto">
		<div class="container">
			<div class="row">
				<div class="parrafo wow zoomIn" data-wow-duration="0.5s">
					<h2>Therapeutic management</h2>
				<br/>
				<p>Monitor neurological signs and symptoms, especially non-specific ones such as memory impairment, dizziness, confusion, change in character, hallucinations, seizures...</p>
				<br/>
				<p>Evaluate in any degree, complete study with electromyogram and study of nerve conduction and refer a Neurology specialist to start specific symptomatic treatment of the condition.</p>


				<div class="marco wow fadeIn">
				<p><span class="decorado">&nbsp;GRADE 1:&nbsp;</span> <span class="turquesa">Asymptomatic or minimal clinical discomfort</span>.</p>
				<p>Does not require discontinuation of the drug.</p>
				<br/>
				<p>Perform a complete clinical examination. Monitor the clinical course of the symptoms.</p>

				</div>


				<br/>

				<div class="marco wow fadeIn">
				<p><span class="decorado">&nbsp;GRADE 2:&nbsp;</span> <span class="turquesa">Moderate symptoms that limit the instrumental daily living activities</span>.</p>
				<br/>
				<p>In the case of acute motor neurotoxicity or neuropathy, stop the treatment until resolution or improvement to <span class="turquesa">GRADE 1</span>. In case of neuropathy or neuropathic pain, consider treatment discontinuation until resolved or improved to <span class="turquesa">GRADE 1</span>.</p>
				<br/>
				<p>Assessment by a neurologist.</p>
				<br/>
				<p>Start Prednisolone at 0.5-1 mg/kg/day orally or equivalent intravenous dose.</p>
				<br/><p>In the case of neuropathic pain, add analgesics (Gabapentin, Duloxetine).</p>
				<br/><p>If the symptoms do not improve despite treatment, treat as GRADE 3-4.</p>
				<br/>
				</div>

				<br/>

				<div class="marco wow fadeIn">
				<p><span class="decorado">&nbsp;GRADE 3/4:&nbsp;</span> <span class="turquesa">Severe symptoms which limit basic daily living activities. Risk that compromises the patient’s life</span>.</p>
				<br/>
				<p>In the case of <span class="turquesa">GRADE 3</span>: Discontinue treatment until resolution or improvement to <span class="turquesa">GRADE 1</span>. If no improvement is seen in 30 days or in case of <span class="turquesa">GRADE 4</span>, discontinue the drug permanently.</p>
				<br/>
				<p>Assessment by a neurologist and complementary studies (brain MRI, lumbar puncture, nerve or muscle or skin biopsy if indicated by clinical practice).</p>
				<br/>
				<p>Start Methylprednisolone 1-2 mg/kg/day intravenously (or equivalent dose)</p>
				<br/>
				<p>If symptoms do not improve in 3-5 days despite treatment, assess treatment with intravenous IgG immunoglobulins or plasmapheresis, especially in cases of Guillain-Barré syndrome, and treatment with Pyridostigmine in cases of Myasthenia Gravis.</p>
				<br/>
				<p>Once the clinical picture has stabilised, maintain for at least 28 days before starting a decreasing corticosteroid regimen.</p>
			</div>

				<br/>


				<div class="marco wow fadeIn">
				<p><span class="decorado">&nbsp;GRADE 5:&nbsp;</span> <span class="turquesa">Death</span>.</p>
				</div>
				<br/>



			</div>
		</div>
	</div>
	</section>

	<section class="counterUp">
		<div class="counter_overlay">
			<div class="container">
				<div class="row">
					<div class="main_counter_content text-center">
						<div class="col-md-12 col-sm-12 col-xs-12">


							<h2>CLINICAL CASE</h2>
							<br/> <img src="images/pacienteICON.png" alt="" height="40px"/> <br/> <br/> <br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> A 59-year-old patient with T3-T4N0M0 non-small cell lung cancer (NSCLC). PDL1 negative, non-translocated ALK, EGFR Wild Type.</p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> 1st treatment: CT-RT (Cisplatin-Etoposide) in 2015 with partial response but the appearance of new left UL pulmonary lesion.</p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> 2nd treatment with palliative chemotherapy: Pemetrexed, starting on 24/04/16 for a total of 3 cycles with disease progression.</p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> 3rd treatment with nivolumab started in 06/2016.</p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> The patient was admitted from 22-25/05/18 for acute bronchitis. Radiological assessment in May 2018 with stable disease and no signs of pneumonitis (ruled out immunotherapy-related pulmonary toxicity). Therefore, the patient continued treatment with Nivolumab.</p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> The patient was admitted from 4-7/06/18 due to exacerbation of the bronchitis symptoms, so the Nivolumab treatment was not administered until 19/07/18 after stopping the corticosteroid treatment with prednisone.</p>
							<br/><br/> <img src="images/medicinas.png" alt="" height="40px"/> <br/>
							<p><span class="negrita">The patient continued to have good tolerance of the treatment with Nivolumab, but after the last cycle:</span></p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> Patient haemodynamically stable, afebrile.</p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> Sensory deficit in the lower left limb that requires a crutch when walking due to the risk of falling.</p>

							<br/><br/>




							<div class="marcoOSCURO wow fadeIn">

							<form>
							<br/> <br/> <br/>
							<h2>What grade would you assign to this patient? And what actions do you think we should take?</h2>
							<br/> <br/> <br/> <br/>
							<label class="container">GRADE 1
								<input type="radio" name="pregunta1" id="p2">
								<span class="checkmark"></span>
							</label>
							<br/>
							<label class="container">GRADE 2
								<input type="radio" name="pregunta1" id="p1">
								<span class="checkmark"></span>
							</label>
							<br/>
							<label class="container">GRADE 3
								<input type="radio" name="pregunta1" id="p3">
								<span class="checkmark"></span>
							</label>
							</form>


							<div class="pregunta wow fadeIn" data-wow-duration="1s">
								<a href="#"><img onclick="resultado();return false;" src="images/profesora.png" alt="" height="90px"/></a>
							</div>


								<div id="flotante" style="display:none;">
									<br/><br/><h2>Correct!</h2>
									<br/>
									<p>This is a grade 2 sensory deficit, so we completed the study with an imaging test (magnetic resonance imaging of the dorso-lumbar spine) to rule out compression on the nerve root and an electromyogram evidencing signal alteration due to moderate sensory deficit. The patient had a correct complete blood test, with no history of changing their concomitant medication, history of radiotherapy in the area. The patient required suspension of treatment with Nivolumab, and we consulted Neurology After eliminating all possible causes, it was deemed an immune-mediated grade 2 peripheral sensory neuropathy. We started Prednisolone 0.5 mg/kg/day orally with resolution of symptoms after 30 days of treatment, which is why the gradual decrease in corticosteroids began. The patient was able to resume treatment with Nivolumab with no further episodes presented.</p>

								</div>
								<div id="flotanteIncorrecto" style="display:none;">
									<br/><br/>
									<h2>This is not correct. Try again :)</h2>

								</div>


							</div>



							<br/>

							<div class="contorno wow fadeIn">
							<h2>REMEMBER <span class="negrita">:</span></h2>
							<br/>
							<p><span class="negrita">•</span> It is important to remember non-specific neurological presentation patterns such as memory alteration, dizziness, confusion, change in character, hallucinations, seizures, and sensory-motor alterations, since this will allow us to detect and diagnose a rare pathology among the immuno-mediated toxicities.</p>
							</div>
						</div>
					</div>
				</div>
			</div>
		</div>
	</section>




	<section>
	 <div class="container">
		 <div class="row">

			 <div class="wedo_content_area">

				 <div class="col-md-6 col-sm-6 col-xs-12">
					 <div class="contornoActivo wow fadeIn" data-wow-duration="1s">
						 <div class="single_right_text">
							 <a href="toxicidad01.html"><h4 class="gris">3.1 GASTROINTESTINAL TOX.</h4></a>
						 </div>
					 </div>
				 </div>

				 <div class="col-md-6 col-sm-6 col-xs-12">
					 <div class="contornoActivo wow fadeIn" data-wow-duration="1s">
						 <div class="single_right_text">
							 <a href="toxicidad02.html"><h4 class="gris">3.2 PULMONARY TOXICITY</h4></a>
						 </div>
					 </div>
				 </div>

				 <div class="col-md-6 col-sm-6 col-xs-12">
					 <div class="contornoActivo wow fadeIn" data-wow-duration="1s">
						 <div class="single_right_text">
							 <a href="toxicidad03.html"><h4 class="gris">3.3 RENAL TOXICITY</h4></a>
						 </div>
					 </div>
				 </div>

				 <div class="col-md-6 col-sm-6 col-xs-12">
					 <div class="contornoActivo wow fadeIn" data-wow-duration="1s">
						 <div class="single_right_text">
							 <a href="toxicidad04.html"><h4 class="gris">3.4 LIVER TOXICITY</h4></a>
						 </div>
					 </div>
				 </div>

				 <div class="col-md-6 col-sm-6 col-xs-12">
					 <div class="contornoActivo wow fadeIn" data-wow-duration="1s">
						 <div class="single_right_text">
							 <a href="toxicidad05.html"><h4 class="gris">3.5 ENDOCRINE TOXICITY</h4></a>
						 </div>
					 </div>
				 </div>

				 <div class="col-md-6 col-sm-6 col-xs-12">
					 <div class="contornoActivo wow fadeIn" data-wow-duration="1s">
						 <div class="single_right_text">
							 <a href="toxicidad06.html"><h4 class="gris">3.6 CUTANEOUS TOXICITY</h4></a>
						 </div>
					 </div>
				 </div>

				 <div class="col-md-6 col-sm-6 col-xs-12">
					 <div class="contornoActivo wow fadeIn" data-wow-duration="1s">
						 <div class="single_right_text">
							 <a href="toxicidad07.html"><h4 class="gris">3.7 NEUROLOGICAL TOXICITY</h4></a>
						 </div>
					 </div>
				 </div>

				 <div class="col-md-6 col-sm-6 col-xs-12">
					 <div class="contorno wow fadeIn" data-wow-duration="1s">
						 <div class="single_right_text">
							 <a href="toxicidad08.html"><h4>3<span class="turquesa">.8</span> OTHER TOXICITIES</h4></a>
						 </div>
					 </div>
				 </div>
			 </div>
		 </div>
	 </div>
	</section>


	<footer id="footer" class="footer">
		<div class="container">
			<div class="row">
				<div class="main_footer text-center wow zoomIn" data-wow-duration="1s">
					<p class="centrado"><a href="https://www.e-oncologia.org/"><img src="images/LOGOeonco.png" alt="" height="22px"/></a></p>
				</div>
			</div>
		</div>
	</footer>

	<!-- STRAT SCROLL TO TOP -->

	<div class="scrollup">
		<a href="#"><img src="images/up.png" alt=""/></a>
	</div>






	<script type="text/javascript" src="js/jquery/jquery.js"></script>

	<script type="text/javascript" src="js/script.js"></script>

	<script type="text/javascript" src="js/bootstrap/bootstrap.min.js"></script>

	<script type="text/javascript" src="js/fancybox/jquery.fancybox.pack.js"></script>

	<script type="text/javascript" src="js/nivo-lightbox/nivo-lightbox.min.js"></script>

	<script type="text/javascript" src="js/owl-carousel/owl.carousel.min.js"></script>

	<script type="text/javascript" src="js/test.js"></script>




	<script type="text/javascript" src="js/jquery-easing/jquery.easing.1.3.js"></script>
	<script type="text/javascript" src="js/wow/wow.min.js"></script>
	<!--<script type="text/javascript" src="js/counterup/counterup.min.js"></script>-->

	<!--<script src="http://cdnjs.cloudflare.com/ajax/libs/waypoints/2.0.3/waypoints.min.js"></script>-->
	<!--<script type="text/javascript" src="js/counterup/jquery.counterup.min.js"></script>-->


	<script type="text/javascript" src="js/isotop/isotope.min.js"></script>
	<script type="text/javascript" src="js/isotop/isotop.function.js"></script>

	<script type="text/javascript" src="js/masonry/masonry.min.js"></script>

	<script type="text/javascript" src="js/mixitup/jquery.mixitup.min.js"></script>
	<script type="text/javascript" src="js/masonry/masonry.pkgd.min.js"></script>
</body>
</html>
